Can early-life antibiotic exposure improve resilience after antibiotics?

Does early antibiotic exposure protect or harm? The evidence points to harm.

The core finding across these 12 studies is that early-life antibiotics do not build resilience — they are consistently associated with a higher risk of several chronic conditions later in childhood. A large Swedish study of over 720,000 children found that those given antibiotics in their first year had a 52% higher risk of developing atopic dermatitis (eczema) compared to unexposed children [1]. Similarly, a Danish study of nearly a million children linked antibiotic use in the first year to a 40% higher risk of Crohn's disease, with the risk jumping to 4 times higher for children who received 6 or more courses [2]. An Australian study of over 4,300 children found that any antibiotic exposure before age 2 more than doubled the risk of early-persistent asthma [3]. These are not small effects, and they are seen across different countries and conditions.

However, the story is more nuanced. Several studies show that these risks are partly due to the underlying infections that prompted the antibiotics, not the drugs themselves. For example, the Swedish eczema study found that when they compared siblings (who share genetics and home environment), the increased risk dropped from 52% to 24%, meaning family factors play a big role [1]. A meta-analysis of autism and ADHD studies found that the apparent link to antibiotics disappeared entirely when comparing siblings [4]. A systematic review on asthma concluded that after accounting for respiratory infections and family history, the remaining risk was small and likely due to the severity of the illness, not the antibiotic [8]. So the antibiotics themselves may not be the sole cause, but they are a marker of increased risk.

How do antibiotics disrupt the gut — and can anything help?

The biological mechanism behind these risks is clear: antibiotics in early life dramatically alter the developing gut microbiome. A randomized trial of 147 newborns given antibiotics for suspected sepsis found that treatment immediately shifted the gut bacteria, reducing beneficial Bifidobacterium and increasing potentially harmful Klebsiella and Enterococcus species [5]. These changes partially normalized over 12 months, but the type of antibiotic mattered — amoxicillin plus cefotaxime caused the largest disruption, while penicillin plus gentamicin caused the least [5]. Another study in mice showed that early antibiotic use severely reduced microbial diversity and short-chain fatty acids (key molecules for immune health), with effects lasting into adulthood and making the animals more susceptible to allergic airway inflammation [9].

Importantly, breastfeeding appears to be a powerful countermeasure. A 2025 study of 66 mother-infant pairs found that exclusive breastfeeding in the first month accelerated the reduction of antibiotic-resistance genes in the infant gut and lowered the overall resistance burden at 6 months [7]. Breastfeeding promoted Bifidobacterium growth, which helped suppress harmful bacteria carrying resistance genes [7]. This suggests that while antibiotics disrupt the microbiome, breastfeeding can help restore resilience — a practical step parents can take.

Are there situations where antibiotics don't raise risk?

Yes, the evidence is not uniform. One Italian study of over 73,000 children found no significant association between early antibiotic exposure and eczema after accounting for the timing of the diagnosis — the apparent link was likely due to 'protopathic bias,' meaning the antibiotics were given for early symptoms of eczema itself, not causing it [6]. A small U.S. study of 4,106 infants actually found a lower risk of eczema in babies exposed to antibiotics in the first month of life, suggesting a possible 'critical window' for immune tolerance [10]. However, this finding is an outlier and contradicts the much larger Swedish study [1] and the broader pattern of increased risk.

The key takeaway is that the risk is not inevitable. It depends on the number of antibiotic courses (more courses = higher risk) [2], the type of antibiotic (broad-spectrum is worse) [5], and the child's genetic and family background [1][4]. For a child with no family history of asthma or eczema, who receives a single, short course of a narrow-spectrum antibiotic, the absolute risk increase is very small — the Danish study calculated that the chance of Crohn's disease by age 11 was only 0.16 per 1,000 children exposed vs. 0.11 per 1,000 unexposed [2]. So while the relative risk is elevated, the absolute risk remains low for most children.

About These Sources

This answer is built on 10 peer-reviewed studies — published from 2021 to 2025, 3 from 2024 or later, 6 in Q1 journals, collectively cited 448 times — selected as the most relevant from 12 studies that passed quality screening, drawn from 46 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions